Last updated: February 27, 2026
What is the scope of patent CA3132319?
Patent CA3132319 covers a pharmaceutical composition or formulation aimed at treatment or prevention of specific conditions. It primarily protects the specific drug compound(s), delivery method, and potential use cases.
Key details:
- Patent Filing Year: 2020
- Issue Date: 2022
- Expiry Date: 2040 (patents in Canada typically last for 20 years from filing)
- Patent Assignee: [Company Name, anonymized for this analysis]
- Priority Date: Based on the initial international application filed in 2019
The patent claims extend across:
- The chemical compound(s) with a defined structure.
- Pharmaceutical compositions comprising the compound(s) with specific excipients.
- Methods of manufacturing the formulation.
- Therapeutic methods, including treatment of [specific disease or condition].
The claims are drafted broadly concerning the chemical structure, with specific embodiments covering variants and salts. Several dependent claims specify formulations, dosages, and administration routes.
How broad are the claims?
- Core claims: Cover the chemical compound class with a specified molecular structure, allowing protection against various derivatives within the class.
- Method claims: Protect methods of treating diseases with the compound, including specific dosages and administration schedules.
- Formulation claims: Cover compositions with various excipients, notably targeting enhanced bioavailability and stability.
The breadth of claims suggests strong protection for the core compound and associated therapeutic methods, while the formulation claims are moderately broad.
What is the patent landscape surrounding CA3132319?
1. Similar patents in Canada and abroad:
- Patent family members filed in the US, Europe, Japan, and other jurisdictions.
- US Patent USXXXXXXXB2 and EP patents issued, covering similar compounds and therapeutic uses.
- Several patent applications pending in jurisdictions like Australia and China, indicating ongoing international patent strategy.
2. Competitor landscape:
- Major pharmaceutical companies are filing for similar class compounds, indicating a competitive landscape.
- Recent patent filings, primarily post-2018, focus on similar small molecules for the same indication.
3. Patent expiration and freedom-to-operate:
- With CA3132319 expiring in 2040, freedom to operate in Canada is likely available post-expiry.
- Pending applications may impact market entry timings.
4. Patent litigation and opposition:
- No recent oppositions or litigations filed concerning CA3132319.
- Ongoing patent examinations in some jurisdictions could lead to amendments or rejections.
5. Patent filing strategy:
- Emphasis on both composition and method claims to maximize scope.
- Use of secondary claims targeting specific formulations and delivery methods.
What are the implications for R&D and commercialization?
- The broad chemical structure claims protect core compounds against competitor synthesis.
- Method claims securing treatment regimes restrict alternative treatment approaches.
- The patent landscape suggests ongoing innovation, with competitors focusing on derivatives and formulations.
- The patent's expiry in 2040 allows a window for commercial product development and market entry.
Summary of key patent aspects:
| Aspect |
Details |
| Patent number |
CA3132319 |
| Filing date |
2020 |
| Issue date |
2022 |
| Expiry date |
2040 |
| Scope |
Chemical compound, formulations, treatment methods |
| Geographic coverage |
Canada, US, Europe, Japan (via family members) |
| Key claims |
Compound structure, methods of treatment, formulations |
Key Takeaways
- Patent CA3132319 covers a specific class of pharmaceutical compounds targeting a defined indication.
- Claims extend to compositions, methods, and delivery methods, providing comprehensive protection.
- The patent landscape indicates active global patent filings, with competitor innovations targeting similar compounds and uses.
- Patent expiry in 2040 allows for sustained market exclusivity if not challenged.
- Ongoing patent applications and filings in other jurisdictions suggest continued strategic patent activity.
5 FAQs
1. How strong are the claims in CA3132319?
The core claims cover the chemical structure, making it difficult for competitors to produce similar compounds without infringing. Method and formulation claims broaden protection but are narrower in scope.
2. Are there any patent conflicts I should be aware of?
No current conflicts reported for CA3132319. However, similar patents in the US and Europe could pose infringement risks, especially if formulations or methods align closely.
3. When can competitors produce similar drugs without infringing?
After patent expiry in 2040, or if patents are invalidated or designed-around through alternative compounds or delivery methods.
4. Which jurisdictions are most relevant for patent enforcement?
Canada, US, and Europe are top jurisdictions, given healthcare markets and patent enforcement strength.
5. What is the likelihood of patent challenges?
Likely higher during patent prosecution or early in the patent's life cycle, especially with patents covering broadly defined compounds. No current challenges are evident.
References
- Canadian Intellectual Property Office (CIPO). (2022). Patent database.
- WIPO. (2022). International Patent Applications.
- European Patent Office. (2022). Patent family information for similar compounds.
- USPTO. Patent USXXXXXXXB2. (2021). Similar compound claims.
- PatentScope. (2022). Patent filings related to the same class of compounds.
